Accordingly, considering of the Fyn/Tim-3 and Bat3/Tim-3 axes could be a promising molecular target for therapeutic interventions in hematological malignancies like CLL. This evidence concerns the gene BAG6 and B-cell chronic lymphocytic leukemia.